Table 1.

Overview of studies investigating the relationship between PSA and clinical outcome metrics

Patient population	Model	Purpose	Reference
Localized PC patients	Joint latent class model PSA, risk of recurrence	Prognosis prediction	30
No PC + early PC patients	Joint latent class model PSA, risk of PC	Diagnosis of PC onset	31
Metastatic CRPC	Logistic regression model of PSA metrics and survival	Prognosis prediction for application as primary trial endpoint	32
Metastatic CRPC	Correlation analysis PSA metrics and survival	Prognosis prediction	14,15
Metastatic CRPC	Cox regression analysis PSA metrics and survival	Prognosis prediction	50

PC, prostate cancer; CRPC, castration-resistant prostate cancer.